Global Chronic Gonadotropin Market Valued at $1.0 billion in 2025, Set to Grow at a 6.3% CAGR

Chronic gonadotropin market was valued at $1.0 billion in 2025 and is projected to reach $1.8 billion by 2035, growing at a CAGR of 6.3% during the forecast Period (2026-2035). Funding and capital inflows into advanced fertility services are increasing, reflecting the growing global demand for reproductive health solutions. This trend contributes to the wider adoption of assisted reproductive technologies (ART) and hormonal therapies, particularly chronic gonadotropins, which are crucial for ovulation induction and fertility treatments, thus driving market growth. For instance, in October 2025, Pluro Fertility and IVF, a company specialised in advanced fertility solutions, raised $15?million in funding, with participation from notable venture investors, reflecting growing capital flows into companies supporting reproductive services and potential demand for related hormone therapies like hCG.

Browse the full report description of “Chronic Gonadotropin Market Size, Share & Trends Analysis by Type (Human Chronic Gonadotropin, Animal Chronic Gonadotropin), By Technology (Female Infertility Treatment, Oligospermia Treatment, Cryptorchidism Treatment, and Others), and By End-User (Hospitals, Medical Centres, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/chronic-gonadotropin-market

Increased Investment in Fertility and Reproductive Health Services

• In March 2025, Arva Health, a femtech startup focused on fertility care and reproductive health services, secured $1?million in pre?seed funding to expand access and technology for fertility services, which contributes indirectly to the chronic gonadotropin therapy ecosystem as demand for treatments rises.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Technology
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Ferring Pharmaceuticals, Fresenius Kabi AG, Merck KGaA,Organon & Co., Sun Pharmaceutical Industries Ltd., among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Chronic Gonadotropin Market Report Segment

By Type

• Human Chronic Gonadotropin
• Animal Chronic Gonadotropin

By Technology

• Female Infertility Treatment
• Oligospermia Treatment
• Cryptorchidism Treatment
• Others

By End?User

• Hospitals
• Medical Centres
• Others (Clinics, Specialty Care Settings)

Global Chronic Gonadotropin Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/chronic-gonadotropin-market